Startup

Nanolive

Description

Nanolive is a Swiss startup that offers revolutionary label-free live cell imaging and analysis solutions, enabling researchers to explore living cells in 3D without damaging them. Their innovative technology provides complete measurements on a sub-cellular scale, allowing for screening across thousands of live cell populations and potential therapeutic use of unperturbed cells. Nanolive's platforms and consumables are designed to accelerate research in various fields such as drug discovery, immuno-oncology, mitochondria & cell metabolism, and neuroscience. With over 300 units installed worldwide, Nanolive's award-winning technology is highly regarded in the scientific community.

Official source

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Description

Official source

Categories (5)

Drug discovery

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology.

Cancer

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other causes. Over 100 types of cancers affect humans. Tobacco use is the cause of about 22% of cancer deaths.

Immune system

The immune system is a network of biological processes that protects an organism from diseases. It detects and responds to a wide variety of pathogens, from viruses to parasitic worms, as well as cancer cells and objects such as wood splinters, distinguishing them from the organism's own healthy tissue. Many species have two major subsystems of the immune system. The innate immune system provides a preconfigured response to broad groups of situations and stimuli.

Cell metabolism

Metabolism (məˈtæbəlɪzəm, from μεταβολή metabolē, "change") is the set of life-sustaining chemical reactions in organisms. The three main functions of metabolism are: the conversion of the energy in food to energy available to run cellular processes; the conversion of food to building blocks for proteins, lipids, nucleic acids, and some carbohydrates; and the elimination of metabolic wastes. These enzyme-catalyzed reactions allow organisms to grow and reproduce, maintain their structures, and respond to their environments.

Human–computer interaction

Human–computer interaction (HCI) is research in the design and the use of computer technology, which focuses on the interfaces between people (users) and computers. HCI researchers observe the ways humans interact with computers and design technologies that allow humans to interact with computers in novel ways. A device that allows interaction between human being and a computer is known as a "Human-computer Interface (HCI)".

Related concepts (32)

Drug discovery

Screening (medicine)

Screening, in medicine, is a strategy used to look for as-yet-unrecognised conditions or risk markers. This testing can be applied to individuals or to a whole population. The people tested may not exhibit any signs or symptoms of a disease, or they might exhibit only one or two symptoms, which by themselves do not indicate a definitive diagnosis. Screening interventions are designed to identify conditions which could at some future point turn into disease, thus enabling earlier intervention and management in the hope to reduce mortality and suffering from a disease.

Cancer screening

Cancer screening aims to detect cancer before symptoms appear. This may involve blood tests, urine tests, DNA tests, other tests, or medical imaging. The benefits of screening in terms of cancer prevention, early detection and subsequent treatment must be weighed against any harms. Universal screening, also known as mass screening or population screening, involves screening everyone, usually within a specific age group. Selective screening identifies people who are known to be at higher risk of developing cancer, such as people with a family history of cancer.

Metabolism

Related people (11)

Johan Auwerx

Johan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways. Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards. Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.

Pierre Magistretti

Pierre J. Magistretti is an internationally-recognized neuroscientist who has made significant contributions in the field of brain energy metabolism. His group has discovered some of the cellular and molecular mechanisms that underlie the coupling between neuronal activity and energy consumption by the brain. This work has considerable ramifications for the understanding of the origin of the signals detected with the current functional brain imaging techniques used in neurological and psychiatric research (see for example Magistretti et al, Science, 283: 496 497, 1999). He is the author of over 100 articles published in peer-reviewed journals. He has given over 80 invited lectures at international meetings or at universities in Europe and North America, including the 2000 Talairach Lecture at the Functional Mapping of the Human Brain Conference. In November 2000 he has been a Mc Donnel Visiting Scholar at Washington University School of Medicine. Pierre J. Magistretti is the President-Elect (2002 2004) of the Federation of European Neuroscience Societies (FENS) which has a membership of over 15000 European neuroscientists. He has been first president of the Swiss Society for Neuroscience (1997-1999) and the first Chairman of the Department of Neurosciences of the University of Lausanne (1996 1998). Pierre J. Magistretti is Professor of Physiology (since 1988) at the University of Lausanne Medical School. He has been Vice-Dean of the University of Lausanne Medical School from 1996 to 2000. Pierre Magistretti, is Director of the Brain Mind Institute at EPFL and Director of the Center for Psychiatric Neuroscience of the University of Lausanne and CHUV. He is also Director of the NCCR SYNAPSY "the synaptic bases of mental diseases". POSITIONS AND HONORS MAIN POSITION HELD 1988-2004 Professor of Physiology, University of Lausanne Medical School 1996-2000 Vice-Dean for Preclinical Departments, University of Lausanne Medical School 2001-2004 Chairman, Department of Physiology, University of Lausanne Medical School 2004-present Professor and Director, Center for Psychiatric Neuroscience, Department of Psychiatry, University of Lausanne Medical School and Hospitals (UNIL-CHUV) (Joint appointment with EPFL) 2005-2008 Professor and Co-Director, Brain Mind Institute, Federal Institute of Technology (EPFL), Lausanne (Joint appointment with UNIL-CHUV) 2007-present Chairman of the Scientific Advisory Board of Centre dImagerie Biomédicale (CIBM), an Imaging Consortium of the Universities, University Hospitals of Lausanne and Geneva and of Ecole Polytechnique Fédérale de Lausanne 2008-present Professor and Director, Brain Mind Institute, Federal Institute of Technology (EPFL), Lausanne Joint appointment with UNIL-CHUV) 2010-present Director, National Center for Competence in Research (NCCR) The synaptic bases of mental diseases of the Swiss National Science Foundation 2010-present Secretary General, International Brain Research Organization (IBRO) MAIN HONORS AND AWARDS 1997 Recipient of the Theodore-Ott Prize of the Swiss Academy of Medical Sciences 2001 Elected Member of Academia Europaea 2001 Elected Member of the Swiss Academy of Medical Sciences, ad personam 2002 Recipient of the Emil Kraepelin Guest Professorship, Max Planck Institute für Psychiatry, Münich 2006 Elected Professor at Collège de France, Paris, International Chair 2007-2008 2009 Goethe Award for Psychoanalytic Scholarship, Canadian Psychological Association 2011 Camillo Golgi Medal Award, Golgi Fondation 2011 Elected Member of the American College of NeuroPsychopharmacology (ACNP)

Stewart Cole

Professor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.

Related publications (30)